Aspirin may also boost survival in men being treated for prostate cancer. In a study of over 5,000 men with localized prostate cancer, those taking aspirin or another anticoagulant called warfarin were much less likely to suffer metastatic disease. Over the decade the study lasted, those on anti-clotting compounds had a 4 percent chance of dying from their prostate cancer. Those who were not taking aspirin or warfarin had a 10 percent chance of dying during that time. Aspirin was the most beneficial, particularly for men with high-risk prostate cancers.
[American Society for Radiation Oncology annual meeting, San Diego, Nov. 1, 2010]
The People's Perspective on Medicine